688189 南新製藥
按盤價 
10.550 +1.760 (+20.023%) | 2026/03 - 三個月 | 2025/12 | 2024/12 | 2023/12 | 2022/12 | 盈利能力分析 |
| 淨資產收益率 ROE (%) | -1.708 | -15.917 | -30.937 | -1.631 | -5.725 |
| 總資產報酬率 ROA (%) | -1.659 | -13.475 | -23.557 | -1.161 | -3.794 |
| 投入資產回報率 ROIC (%) | -1.678 | -14.006 | -24.736 | -1.213 | -4.024 | 邊際利潤分析 |
| 銷售毛利率 (%) | 25.214 | 31.503 | 52.505 | 83.337 | 85.788 |
| 營業利潤率 (%) | -57.985 | -93.413 | -149.416 | -3.248 | -10.287 |
| 息稅前利潤/營業總收入 (%) | -58.591 | -93.470 | -150.223 | -2.457 | -9.585 |
| 淨利潤/營業總收入 (%) | -56.817 | -105.515 | -153.075 | -3.470 | -13.743 | 收益指標分析 |
| 經營活動淨收益/利潤總額(%) | 78.774 | 60.150 | 20.442 | -144.933 | -53.804 |
| 價值變動淨收益/利潤總額(%) | 0.000 | 0.000 | 0.000 | 70.700 | 7.775 |
| 營業外收支淨額/利潤總額(%) | 0.021 | 0.126 | 0.152 | -0.925 | 0.755 | 償債能力分析 |
| 流動比率 (X) | 4.231 | 4.275 | 2.290 | 2.943 | 2.308 |
| 速動比率 (X) | 3.756 | 3.892 | 2.110 | 2.873 | 2.266 |
| 資產負債率 (%) | 11.720 | 11.991 | 28.151 | 25.407 | 33.676 |
| 帶息債務/全部投入資本 (%) | 1.476 | 1.166 | 18.784 | 20.447 | 29.321 |
| 股東權益/帶息債務 (%) | 6,647.377 | 8,436.399 | 430.395 | 387.338 | 239.254 |
| 股東權益/負債合計 (%) | 832.095 | 807.263 | 272.160 | 298.084 | 199.680 |
| 利息保障倍數 (X) | 98.701 | -1,548.718 | 259.234 | -3.226 | -12.285 | 營運能力分析 |
| 應收賬款周轉天數 (天) | 113.455 | 293.768 | 512.185 | 339.717 | 339.337 |
| 存貨周轉天數 (天) | 180.309 | 179.680 | 137.810 | 94.579 | 160.282 |
| 備註： | 即時報價更新時間為 11/05/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
